Siyuan Zheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2889143/publications.pdf

Version: 2024-02-01

45	14,704	257101 24	264894 42
papers	citations	h-index	g-index

51	51	51	22724
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 80-89.	0.9	2
2	Signature-scoring methods developed for bulk samples are not adequate for cancer single-cell RNA sequencing data. ELife, 2022, 11, .	2.8	22
3	M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. Cancer Research, 2022, 82, 1872-1889.	0.4	29
4	PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. Nucleic Acids Research, 2021, 49, D1321-D1327.	6.5	9
5	Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. Nature Communications, 2021, 12, 139.	5.8	39
6	SNAI2-Mediated Repression of BIM Protects Rhabdomyosarcoma from Ionizing Radiation. Cancer Research, 2021, 81, 5451-5463.	0.4	13
7	A modular master regulator landscape controls cancer transcriptional identity. Cell, 2021, 184, 334-351.e20.	13.5	78
8	EGFRAmplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clinical Cancer Research, 2020, 26, 1395-1407.	3.2	26
9	Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. Nature Communications, 2020, 11, 3669.	5.8	14
10	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chemical Biology, 2020, 27, 538-550.e7.	2.5	14
11	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	2.9	103
12	Tie2â€“FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Research, 2019, 79, 5088-5101.	0.4	17
13	Prospective Clinical Sequencing of Adult Glioma. Molecular Cancer Therapeutics, 2019, 18, 991-1000.	1.9	15
14	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nature Genetics, 2018, 50, 708-717.	9.4	212
15	TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Research, 2018, 46, D1144-D1149.	6.5	179
16	Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Reports, 2018, 24, 463-478.e5.	2.9	21
17	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	2.3	31
18	Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nature Genetics, 2017, 49, 349-357.	9.4	476

#	Article	IF	Citations
19	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	13.5	1,794
20	Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro-Oncology, 2017, 19, 786-795.	0.6	87
21	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	2.9	416
22	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell, 2017, 32, 42-56.e6.	7.7	1,282
23	Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature Genetics, 2017, 49, 75-86.	9.4	74
24	ARID1B alterations identify aggressive tumors in neuroblastoma. Oncotarget, 2017, 8, 45943-45950.	0.8	19
25	Benchmarking: contexts and details matter. Genome Biology, 2017, 18, 129.	3.8	9
26	Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget, 2017, 8, 21741-21753.	0.8	16
27	APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death. Oncotarget, 2017, 8, 54285-54296.	0.8	15
28	TMOD-31. AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS. Neuro-Oncology, 2016, 18, vi213-vi213.	0.6	0
29	MSK1-Mediated Î²-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma. Molecular Cancer Therapeutics, 2016, 15, 1656-1668.	1.9	25
30	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
31	TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT. Neuro-Oncology, 2016, 18, vi202-vi202.	0.6	11
32	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
33	Advances in Computational Genomics. BioMed Research International, 2015, 2015, 1-2.	0.9	0
34	GENO-36GLIOMA SPHERE-FORMING CELLS REVEAL INTRINSIC GLOBAL HYPERMETHYLATION ASSOCIATED WITH GBM RADIATION RESISTANCE. Neuro-Oncology, 2015, 17, v99.5-v100.	0.6	0
35	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Research, 2015, 25, 316-327.	2.4	343
36	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582

#	Article	IF	Citations
37	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Research, 2015, 75, 4131-4142.	0.4	38
38	PRADA: pipeline for RNA sequencing data analysis. Bioinformatics, 2014, 30, 2224-2226.	1.8	147
39	Silent Mutations Make Some Noise. Cell, 2014, 156, 1129-1131.	13.5	33
40	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nature Communications, 2014, 5, 3963.	5.8	143
41	ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. Cell Reports, 2014, 6, 313-324.	2.9	106
42	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
43	Intragenic breakpoint. Cell Cycle, 2013, 12, 3705-3706.	1.3	1
44	A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes and Development, 2013, 27, 1462-1472.	2.7	74
45	Studying a Complex Tumor. Cancer Journal (Sudbury, Mass), 2012, 18, 107-114.	1.0	26